World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 6
Page: 388-404

TARGETING THE DOPAMINERGIC SYSTEM IN ALZHEIMER'S DISEASE: FROM PATHOPHYSIOLOGY TO THERAPEUTIC POTENTIAL OF BROMOCRIPTINE: A COMPREHENSIVE LITERATURE REVIEW

Salman Abdullah M. Alharthi*[1], Mohammed Alsieni[2], Mai Abdul Alim Abdul Sattar Ahmad[2]

[1]King Abdulaziz Specialist Hospital, Taif, Saudi Arabia.

[2]Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.

Article Received: 06 April 2026 | | ***Article Revised: 27 April 2026*** | | ***Article Accepted: 17 May 2026***

***Corresponding Author: Salman Abdullah M. Alharthi**
King Abdulaziz Specialist Hospital, Taif, Saudi Arabia.
DOI: https://doi.org/10.5281/zenodo.20445011

How to cite this Article: Salman Abdullah M. Alharthi, Mohammed Alsieni, Mai Abdul Alim Abdul Sattar Ahmad (2026) TARGETING THE DOPAMINERGIC SYSTEM IN ALZHEIMER'S DISEASE: FROM PATHOPHYSIOLOGY TO THERAPEUTIC POTENTIAL OF BROMOCRIPTINE: A COMPREHENSIVE LITERATURE REVIEW. World Journal of Pharmaceutical Science and Research, 5(6), 388-404.

Copyright © 2026 Salman Abdullah M. Alharthi | World Journal of Pharmaceutical Science and Research.
This work is licensed under creative Commons Attribution-NonCommercial 4.0 International license (CC BY-NC 4.0).

ABSTRACT

Background: Alzheimer's disease (AD) affects over 40 million individuals worldwide, with current therapeutic approaches showing limited efficacy. While the cholinergic hypothesis has dominated AD drug development, emerging evidence suggests that dopaminergic system dysfunction may play a crucial role in AD pathophysiology. Bromocriptine, a selective dopamine D2 receptor agonist, has demonstrated neuroprotective properties and potential therapeutic benefits in preclinical AD models. **Aim:** This comprehensive review critically evaluates the current understanding of dopaminergic dysfunction in AD and systematically assesses the therapeutic potential of bromocriptine as a novel treatment approach, analyzing mechanistic pathways, preclinical evidence, and clinical implications. **Methods:** A systematic literature search was conducted across PubMed, Embase, Web of Science, and Cochrane databases from inception to September 2025. Search terms included combinations of "Alzheimer's disease," "dopamine," "bromocriptine," "D2 receptor," and "neurodegeneration." Studies were selected based on their relevance to AD pathophysiology, dopaminergic mechanisms, and the therapeutic effects of bromocriptine. **Results:** The review synthesizes evidence from 93 studies demonstrating that dopaminergic dysfunction occurs early in AD progression, with D2 receptor availability in the hippocampus correlating strongly with memory performance. Bromocriptine uniquely modulates amyloid-β processing through D2 receptor activation, reduces neuroinflammation via PP2A/JNK pathways, and provides neuroprotection against glutamate excitotoxicity. Unlike other dopamine agonists, bromocriptine specifically targets amyloidogenic pathways while maintaining cognitive enhancement properties. **Conclusions:** Bromocriptine represents a promising therapeutic candidate for AD treatment through its multi-target approach addressing dopaminergic deficits, amyloid pathology, and neuroinflammation. However, clinical translation requires carefully designed trials considering dosing optimization, patient stratification, and safety profiles in elderly populations. The evidence supports bromocriptine as a potential disease-modifying therapy that could complement existing cholinesterase inhibitors.

KEYWORDS: Alzheimer's disease, dopamine, bromocriptine, D2 receptor, neurodegeneration, amyloid-beta, neuroprotection.

1. INTRODUCTION

Alzheimer's disease (AD) affects approximately 55 million people worldwide, with prevalence projected to reach 139 million by 2050.[1] The global economic burden exceeds $1.3 trillion annually, positioning dementia as a leading healthcare crisis.[2] Despite decades of research, current therapeutic options remain severely limited, offering only modest symptomatic benefits without meaningful disease modification.

Traditional AD treatments, including cholinesterase inhibitors and memantine, yield effect sizes ranging from -0.26 to -0.49 on cognitive scales, with clinical improvements often imperceptible to patients and their families.[3] Recently approved anti-amyloid antibodies, which have achieved regulatory milestones, demonstrate limited clinical efficacy. Lecanemab shows a 27% relative reduction in cognitive decline, translating to minimal functional improvements, while carrying substantial safety risks, including up to 39% incidence of amyloid-related imaging abnormalities (ARIA) in APOE4 homozygotes.[4,5] These treatments' prohibitive costs ($28,200 annually for lecanemab) and infrastructure requirements restrict access to fewer than 20% of AD patients.[6]

Emerging evidence reveals dopaminergic dysfunction as an early and fundamental component of AD pathophysiology, offering novel therapeutic opportunities. Neuroimaging studies demonstrate a 34% reduction in hippocampal D2 receptor availability in AD patients, correlating directly with memory performance and executive dysfunction.[7]

Recent molecular studies have shown that dopamine neuron degeneration in the ventral tegmental area occurs at pre-plaque stages, leading to hippocampal hyperexcitability through D2-receptor-mediated dysfunction.[8] Clinically, this manifests as apathy affecting 49% of AD patients, and motivational impairments that precede memory symptoms and predict accelerated cognitive decline.[9]

Critically, recent discoveries demonstrate that dopamine treatment promotes neprilysin production, leading to β-amyloid plaque degradation in AD models, suggesting dopaminergic agents could provide disease-modifying effects through mechanisms distinct from direct amyloid targeting.[10,11]

Bromocriptine emerges as the most compelling dopaminergic candidate for AD therapeutics, supported by breakthrough mechanistic discoveries and established clinical safety data. The seminal study by Liu et al.[12] demonstrated that bromocriptine ameliorates Aβ1-42-induced memory deficits and neuroinflammation through a novel DRD2/β-arrestin 2/PP2A/JNK signaling axis, providing the first direct evidence of anti-neuroinflammatory effects in AD models. Bromocriptine's unique profile combines excellent blood-brain barrier penetration, proven cardiovascular safety, and multi-modal neuroprotective mechanisms, including NLRP3 inflammasome suppression and oxidative stress reduction.[13,14]

The clinical translation potential is supported by over 30 years of safety data from applications in Parkinson's disease and diabetes, with established dosing protocols and well-characterized side effect profiles. Unlike novel therapeutic entities requiring extensive safety evaluation, bromocriptine's repurposing pathway offers accelerated development timelines and reduced regulatory barriers.[15]

This comprehensive review synthesizes current evidence supporting bromocriptine as a repurposed therapeutic for AD, examining its pharmacological mechanisms, preclinical efficacy data, and positioning within the evolving treatment landscape. This review aims to evaluate the therapeutic potential of bromocriptine for Alzheimer's disease by analyzing

the mechanisms of dopaminergic dysfunction, assessing both preclinical and clinical evidence, and examining its positioning within precision medicine and combination therapy approaches.

2. METHODS

2.1 Literature Search Strategy

A comprehensive literature search was conducted across PubMed/MEDLINE, Embase, Web of Science, and Cochrane Library databases from inception through September 2025. The search strategy combined terms related to Alzheimer's disease ("Alzheimer's disease" OR "dementia" OR "cognitive impairment"), dopaminergic dysfunction ("dopamine" OR "dopaminergic" OR "D2 receptor" OR "D3 receptor"), and bromocriptine ("bromocriptine" OR "parlodel"). Additional searches targeted specific mechanisms, including amyloid-beta interactions, neuroinflammation, and tau pathology in relation to dopaminergic systems.

2.2 Study Selection Criteria

Studies were included if they examined dopaminergic mechanisms in AD pathophysiology, investigated the effects of bromocriptine on AD-related pathology, reported changes in dopamine receptors in AD patients, or explored the neuroprotective mechanisms of dopamine agonists. Both preclinical and clinical studies were included, encompassing in vitro, animal model, and human research. Articles were restricted to English-language, peer-reviewed publications. Studies focusing solely on Parkinson's disease without AD relevance, case reports, conference abstracts, and editorial pieces were excluded.

2.3 Evidence Synthesis Approach

A narrative synthesis was conducted due to heterogeneity in study designs and outcome measures. Evidence was organized thematically around AD pathophysiology theories, dopaminergic dysfunction, bromocriptine mechanisms, preclinical efficacy, and clinical translation potential.

3. Age-Related Disorders and Dementia: Current Landscape

As global aging rates continue to rise, the prevalence of dementia has become one of the most complex and significant issues associated with both medical and social circumstances of the 21st century [16]. Among the various forms of late-onset dementia, the most common types include Alzheimer's disease (AD), Lewy body dementia, vascular dementia, and frontotemporal dementia. Each of these types is distinct in its underlying pathology and manifestation, yet they share commonalities in terms of the cognitive and functional impairments they produce in affected individuals.[17]

Alzheimer's disease, recognized as the most prevalent form of dementia, is characterized by a progressive decline in cognitive functions as well as behavioral capabilities. This gradual deterioration not only affects the individuals who are diagnosed with the condition but also profoundly influences the overall quality of life for their families and caregivers.[18] The challenges posed by this illness can be both emotionally and physically taxing, leading to significant implications for the social dynamics and everyday lives of those involved.

About 40 million people around the world are living with dementia. In 2019, the total societal expenses related to dementia were estimated at $1.313 trillion for 55.2 million affected individuals, which amounts to about $23,796 per person. Of this total, direct medical expenses accounted for $213.2 billion (16%), while social sector costs, including

long-term care, totaled $448.7 billion (34%). Informal caregiving costs accounted for $651.4 billion, making up 50% of the total.[19]

According to the Saudi Arabian Ministry of Health, approximately 130,000 individuals were diagnosed with Alzheimer's disease (AD) in 2020. This figure is projected to increase substantially in the coming decades, largely attributable to the demographic shift associated with population aging. Specifically, the proportion of individuals aged 60 years and above in Saudi Arabia is expected to rise from 4.4% of the total population in 2021 to nearly 18% by 2050.[20]

Furthermore, individuals diagnosed with AD display a variety of symptoms, many of which may develop over time. One of the earliest clinical indicators associated with these symptoms is difficulty recalling recent conversations, which can result in noticeable memory loss. Moreover, both depressive disorder and apathy have been significantly associated with the progression of Alzheimer's disease.[21]

4. Theories on AD Pathogenesis: A Critical Assessment

The current understanding of AD pathogenesis rests on several competing yet potentially complementary hypotheses. Critical synthesis of the existing literature reveals that no single hypothesis adequately explains the full spectrum of AD pathology, suggesting a multifactorial etiology that necessitates multi-target therapeutic approaches.[22,23] This analytical framework challenges the traditional reductionist approach to AD drug development and provides the foundation for exploring alternative therapeutic pathways, including dopaminergic modulation.

4.1 The Tau Hypothesis: Beyond Neurofibrillary Tangles

Paired helical filaments of tau (PHF-tau) and neurofibrillary tangles (NFTs) are formed when the tau protein undergoes hyperphosphorylation. This process modifies the tau protein in a way that promotes the aggregation of these structures, contributing to the progression of neurodegenerative disorders.[24-28] The tau hypothesis has evolved significantly since its initial formulation, with substantial evidence supporting the correlation between tau pathology and cognitive decline through clear mechanistic pathways from hyperphosphorylation to neuronal dysfunction.[29]

Previously, research on AD was focused mainly on amyloid beta (Aβ). The tau protein undergoes several post-translational alterations, particularly hyperphosphorylation. This process culminates in the pathological aggregation of tau protein, a hallmark feature of Alzheimer's disease.[30] Recent genetic discoveries have identified tau protein as a crucial component in the development of a pathological condition in specific subgroups of frontotemporal dementias, representing a diverse category of tauopathies characterized by the co-occurrence of dementia and various movement disorders.[31]

The transformation of tau monomers into oligomeric assemblies significantly enhances tau protein accumulation. This excessive buildup facilitates tau's interaction with helical filaments, ultimately leading to the formation of neurofibrillary tangles (NFTs) through processes of hyperphosphorylation. It is widely posited that these intermediate tau oligomers constitute a particularly neurotoxic species, critically involved in mediating synaptic dysfunction associated with Alzheimer's disease.[32-35]

4.2 The Amyloid Cascade Hypothesis: Reconsidering the Evidence

Alzheimer's disease pathology is distinctly characterized by the presence of amyloid plaques, which are widely accepted as a hallmark feature of the condition. The amyloid cascade hypothesis posits that the pathological progression of AD fundamentally relies on the formation and accumulation of these plaques within the brain.[36]

These amyloid plaques originate from the aggregation of amyloid-beta (Aβ) peptides, which are generated through the proteolytic processing of the amyloid precursor protein (APP).

The amyloid-beta (Aβ) protein is widely acknowledged as a fundamental pathological hallmark of Alzheimer's disease and plays an essential role in its onset and progression.[37] This protein is generated through the intricate proteolytic cleavage of the amyloid precursor protein (APP), a process that results in the accumulation of extracellular amyloid plaques within the brain tissue.

However, critical evaluation of the amyloid cascade hypothesis reveals several paradoxes that challenge its continued dominance in AD research. The poor correlation between plaque burden and cognitive symptoms, combined with the failure of multiple anti-amyloid therapies to show meaningful clinical benefit, suggests that amyloid may not be the primary therapeutic target.[38,39] Additionally, the presence of amyloid pathology in cognitively normal individuals raises fundamental questions about the causal relationship between amyloid accumulation and clinical symptoms.

4.3 The Cholinergic Hypothesis: Therapeutic Success but Mechanistic Limitations

The cholinergic hypothesis has significantly advanced the field of Alzheimer's disease research by shifting the focus from merely detailed characterization of neuropathological features to a more contemporary understanding of synaptic neurotransmission.[40-43] This pivotal hypothesis is anchored on three fundamental discoveries: (1) decreased levels of presynaptic cholinergic markers in the cerebral cortex, (2) recognition that the nucleus basalis of Meynert (NBM) constitutes the principal origin of cholinergic projections to the cerebral cortex and experiences significant degeneration in AD, and (3) demonstration that cholinergic antagonists have detrimental effects on memory function while cholinergic agonists enhance memory capabilities.[44-48]

The cholinergic hypothesis stands as the earliest theoretical framework among the various causative theories proposed to explain the initiation and advancement of Alzheimer's disease.[49] The hypothesis received additional support when research demonstrated that cholinesterase inhibitor therapies are associated with significant symptomatic improvements in patients diagnosed with Alzheimer's disease.[50]

Clinical trials demonstrated that tacrine, donepezil, galantamine, rivastigmine, and memantine serve as main therapeutic options and the first medications to be utilized in clinical settings for AD management.[51,52] The cholinergic hypothesis serves as the foundation for the development of four out of the five anti-Alzheimer's disease drugs currently available in the market.[53]

Mechanistic insights reveal that these agents significantly modulate dopaminergic neurotransmission. Recent neurochemical studies demonstrate that donepezil and galantamine enhance dopamine release in cortical and hippocampal regions, suggesting that their therapeutic effects may partially depend on dopaminergic mechanisms.[54-57]

Rivastigmine also improved isolation-rearing-induced prepulse inhibition deficits in mice and increased extracellular dopamine levels in the prefrontal cortex.[58]

4.4 Oxidative Stress and Inflammation Hypotheses

The oxidative stress hypothesis plays a pivotal role in the pathogenesis of Alzheimer's disease. Given the brain's high energy demands, there is an increased reliance on mitochondrial respiration, which subsequently raises the likelihood of generating reactive oxygen species (ROS). The relationship between AD and various forms of molecular oxidative stress is well established, particularly evident in protein nitration, protein oxidation, lipid peroxidation, and glycoxidation.[59-64]

Studies have demonstrated that a decrease in mitochondrial superoxide dismutase (SOD) activity plays a significant role in exacerbating Alzheimer's disease-like pathology and hastening the onset of cognitive and behavioral symptoms.[65-67] In patients with early-stage Alzheimer's disease, reduced levels of total glutathione (GSH) have been observed, suggesting an impairment in the body's antioxidant defense system.[68]

The inflammation hypothesis has gained increasing emphasis within Alzheimer's disease research, underscoring the pivotal role of neuroinflammation and abnormal gliosis as key pathological markers.[69,70] Accumulating evidence suggests that microglial activation and related signaling pathways serve as significant contributors to the risk and development of AD. Research has revealed that serum concentrations of interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were markedly higher in patients diagnosed with Alzheimer's disease compared to control subjects.[71-74]

5. Dopaminergic System and AD: An Underexplored Therapeutic Avenue

5.1 Critical Analysis of Dopaminergic Dysfunction in AD

The dopaminergic system has been extensively studied due to its critical role as a key neurotransmitter involved in cognitive functions and emotion regulation.[75] The natural aging process is associated with numerous changes within the dopaminergic system, with recent research highlighting the vital role of dopamine in modulating mechanisms related to synaptic plasticity.[76]

Extensive research has identified numerous pathological changes occurring within the neurons of the nigrostriatal pathway, including neurofilament triplets, neuropil threads, beta-amyloid (Aβ) plaque accumulation, decreased dopamine levels, and overall neuronal loss. A compelling hypothesis suggests that dysfunction in dopaminergic transmission may significantly contribute to AD pathogenesis.[77]

Dopamine exerts its effects through five distinct receptor subtypes, grouped into two main classes: D1-like receptors (D1R and D5R) and D2-like receptors (D2R, D3R, and D4R). In relation to Alzheimer's disease, the presence of dopamine D2 receptors in the hippocampus has been closely linked to memory performance.[78] Studies suggest that dopamine facilitates cortical excitability primarily via D2-like receptors, while simultaneously activating D1-like receptors to enhance cortical acetylcholine release.

5.2 Mechanistic Convergence: Dopamine and Established AD Pathways

Novel mechanistic insights reveal that dopaminergic interventions could address multiple AD pathways simultaneously.[79,80] Recent studies have provided compelling evidence that dopamine plays a crucial role in counteracting oxidative stress and inflammation triggered by amyloid-beta accumulation during early phases of AD.[77]

This neuroprotective effect is largely mediated through the suppression of inflammatory mediators that contribute to the development of neurofibrillary tangles.

Research has demonstrated that pharmacological agents targeting dopamine D2 and D3 receptor activation, such as rotigotine, show promising potential to enhance neural plasticity in patients diagnosed with Alzheimer's disease.[81]

Dopamine D2 receptors within the hippocampus play a vital role in supporting memory functions affected by AD. A positron emission tomography (PET) study using the radioligand [(11)C]FLB 457 revealed a significant reduction of approximately 34% in D2 receptor availability in the right hippocampus of AD patients compared to healthy control subjects.[82]

6. Bromocriptine as a Potential Treatment for Alzheimer's Disease

6.1 Pharmacological Profile and Mechanism of Action

Bromocriptine is a dopaminergic agonist that selectively targets dopamine D2 receptors (DRD2). Clinically, it is commonly employed in the treatment of hyperprolactinemia-related reproductive disorders and early-stage Parkinson's disease.[83-85] Notably, bromocriptine is also the only dopamine-modulating agent that has received regulatory approval for the treatment of type 2 diabetes mellitus.

Bromocriptine exhibits differential binding affinities across dopamine receptor subtypes. It exhibits high binding affinity for the D3 receptor while also displaying notable affinity for the D2 receptor. However, pharmacological studies have demonstrated that bromocriptine is approximately ten times more potent in activating the D2 receptor relative to the D3 receptor.[86]

6.2 Neuroprotective Mechanisms

Bromocriptine has shown considerable promise in enhancing memory and protecting the nervous system against neurotoxic insults. Empirical evidence suggests that bromocriptine exerts neuroprotective effects by modulating glutamatergic neurotransmission, specifically through the inhibition of excitatory amino acid release via the reversal of glutamate transporter activity.[87]

Bromocriptine has emerged as particularly promising in counteracting the accumulation of amyloid-beta (Aβ). Experimental research has identified bromocriptine as the most efficacious compound among various dopamine receptor agonists evaluated for their impact on Aβ metabolism. Further investigations revealed that its therapeutic efficacy is closely tied to its selective agonism at dopamine receptor D2 (DRD2).[88]

6.3 Anti-inflammatory Properties

Bromocriptine exhibits significant therapeutic promise in AD treatment, particularly through its ability to counteract memory impairments and neuroinflammatory responses triggered by amyloid-beta (Aβ1-42) in murine models. The seminal study by Liu et al.[12] demonstrated that bromocriptine ameliorates Aβ1-42-induced memory deficits and neuroinflammation through a novel DRD2/β-arrestin 2/PP2A/JNK signaling axis.

Mechanistically, bromocriptine-mediated activation of D2 receptors facilitates the recruitment of protein phosphatase 2A (PP2A) and c-Jun N-terminal kinase (JNK) via the scaffold protein β-arrestin 2. This signaling cascade

downregulates JNK-dependent transcription of pro-inflammatory cytokines and suppresses NLRP3 inflammasome activation in microglial cells.[12]

7. Comparative Analysis of Therapeutic Approaches

7.1 Bromocriptine vs. Other Dopamine Agonists

Table 1 presents a comparative analysis of dopamine agonists in AD-related research, highlighting bromocriptine's unique profile among dopaminergic therapeutics.

Table 1: Comparative Analysis of Dopamine Agonists in AD-Related Research.

Drug	Receptor Selectivity	AD-Relevant Mechanisms	Preclinical Evidence	Clinical Status	Limitations
Bromocriptine	D2 > D3 >> D1	• Amyloid-β reduction • Anti-inflammatory • Neuroprotective	• Memory improvement in Aβ models • Reduced neuroinflammation • Enhanced cognitive performance	FDA-approved (other indications)	• Limited AD clinical data • Potential side effects in elderly
Rotigotine	D3 > D2 > D1	• Cortical excitability • Cholinergic restoration	• Enhanced neural plasticity • Improved cognition in AD patients	Phase II trials in AD	• Transdermal application challenges • Cost considerations
Pramipexole	D3 >> D2	• Neuroprotection • Anti-oxidant	• Cognitive benefits in some models	Limited AD studies	• Insufficient AD-specific data
Ropinirole	D2 = D3	• Motor function • Limited cognitive data	• Minimal AD research	Not studied in AD	• No established AD relevance

7.2 Bromocriptine vs. Current AD Therapeutics

Table 2 presents a comprehensive comparison of the mechanisms of action between bromocriptine and established AD treatments.

Table 2: Mechanism of Action Comparison.

Therapeutic Approach	Primary Target	Mechanism	Clinical Efficacy	Bromocriptine Advantage
Cholinesterase Inhibitors (Donepezil, Rivastigmine, Galantamine)	AChE/BuChE	• Acetylcholine elevation • Secondary dopamine effects	• Modest cognitive improvement • MMSE: 2-3 point benefit	• Direct dopaminergic targeting • Multi-pathway effects
NMDA Antagonist (Memantine)	NMDA receptors	• Glutamate modulation • Neuroprotection	• Moderate-severe AD benefit • Functional preservation	• Earlier intervention potential • Anti-amyloid effects
Anti-Amyloid Antibodies (Aducanumab, Lecanemab)	Amyloid-β	• Plaque clearance • Immune activation	• Controversial efficacy • Significant side effects	• Oral administration< • Established safety profile
Tau-targeting agents (Experimental)	Tau protein	• Aggregation inhibition • Clearance enhancement	• Limited clinical success	• Complementary mechanism • Potential tau modulation

7.3 Dosing and Safety Considerations

Table 3 outlines bromocriptine dosing across different indications and proposes considerations for AD application.

Table 3: Bromocriptine Dosing Across Indications and Proposed AD Use.

Indication	Typical Dose Range	Administration	Duration	AD-Specific Considerations
Parkinson's Disease	1.25-100 mg/day	2-3 divided doses	Long-term	• Lower doses may suffice for cognitive benefits • Gradual titration is essential
Hyperprolactinemia	2.5-15 mg/day	1-2 divided doses	Variable	• A similar range may be appropriate for AD
Type 2 Diabetes	0.8-4.8 mg/day	Once daily (QR formulation)	Long-term	• QR formulation may improve compliance
Proposed AD Use	1.25-10 mg/day	1-2 divided doses	Long-term	• Start low (1.25 mg) • Monitor for orthostatic hypotension • Consider drug interactions

8. Clinical Translation: From Bench to Bedside

8.1 Safety Profile in Elderly Populations

Table 4 presents a comprehensive risk-benefit analysis for AD patients considering bromocriptine therapy.

Table 4: Risk-Benefit Analysis for AD Patients.

Risk Category	Specific Concerns	Mitigation Strategies	Monitoring Requirements
Cardiovascular	• Orthostatic hypotension • Cardiac arrhythmias	• Start with low doses • Gradual titration • Morning administration	• Blood pressure monitoring • ECG if indicated • Fall risk assessment
Neuropsychiatric	• Hallucinations • Impulse control disorders	• Patient/caregiver education • Regular psychiatric evaluation	• Behavioral assessments • Family reporting
Gastrointestinal	• Nausea • Constipation	• Take with food • Dietary modifications	• GI symptom monitoring • Bowel movement tracking
Sleep-related	• Sleep attacks • Excessive daytime somnolence	• Avoid evening doses • Sleep hygiene counseling	• Sleep quality assessment • Epworth Sleepiness Scale

8.2 Cost-Effectiveness Analysis

Table 5 provides estimated annual costs for different AD treatment approaches.

Table 5: Cost-Effectiveness Comparison (Estimated Annual Costs).

Treatment Category	Annual Cost Range (USD)	Administration Requirements	Monitoring Costs	Total Healthcare Impact
Bromocriptine	$500-2,000	Oral, self-administered	Routine office visits	Low additional burden
Cholinesterase Inhibitors	$1,200-3,600	Oral, self-administered	Routine monitoring	Established pathway
Anti-Amyloid Antibodies	$26,000-56,000	IV infusion monthly	MRI monitoring, ARIA surveillance	High infrastructure needs
Combination Therapy	$1,700-5,600	Oral medications	Enhanced monitoring	Moderate increase

9. Clinical Decision-Making and Implementation

9.1 Patient Selection Criteria

The optimal candidates for bromocriptine therapy in AD include patients with mild to moderate cognitive impairment (MMSE 15-26) who demonstrate dopaminergic symptoms such as apathy, depression, or sleep disturbances. These

symptoms often precede classical cognitive symptoms and may serve as early biomarkers for therapeutic intervention.[21,82]

9.2 Treatment Protocol

The recommended approach emphasizes gradual dose escalation starting at 1.25 mg daily with weekly titration to 2.5-10 mg/day, balancing therapeutic efficacy with tolerability. This systematic approach minimizes side effects while allowing for individualized dose optimization based on patient response and tolerance.

Comprehensive integration of dopaminergic dysfunction in Alzheimer's disease pathophysiology, showing the complex interplay between established AD pathways and dopaminergic system dysfunction, as shown in **Figure 1**.



Figure 1: Comprehensive integration of dopaminergic dysfunction in Alzheimer's disease pathophysiology.

Figure 2 presents a clinical decision-making algorithm for the implementation of bromocriptine in Alzheimer's disease, providing clinicians with essential decision points for the safe and effective use of this medication.



Figure 2: Clinical decision-making algorithm for bromocriptine implementation in Alzheimer's disease.

A comprehensive comparative analysis of Alzheimer's disease therapeutics across clinical efficacy, safety profile, cost-effectiveness, and mechanistic coverage domains in **Figure 3**.



Figure 3: Comprehensive comparative analysis of Alzheimer's disease.

10. Discussion: Integrating Dopaminergic Dysfunction into AD Therapeutic Paradigms

10.1 Paradigm Shift: Beyond the Cholinergic Monopoly

The therapeutic landscape for Alzheimer's disease has been dominated by the cholinergic hypothesis for over four decades, resulting in a narrow focus on acetylcholine enhancement. This review presents compelling evidence for a paradigm shift toward multi-neurotransmitter approaches, with the dopaminergic system emerging as a critical yet underexplored therapeutic target.

The convergence of multiple lines of evidence from pathological studies showing D2 receptor loss, to functional imaging demonstrating correlation with memory performance, to preclinical studies revealing neuroprotective mechanisms, builds a compelling case for dopaminergic involvement in AD pathophysiology. Notably, the observation that current cholinesterase inhibitors exert significant dopaminergic effects suggests that the therapeutic success attributed to cholinergic enhancement may partially depend on dopaminergic modulation.[54-57]

10.2 Bromocriptine: A Multi-Target Therapeutic Approach

Bromocriptine's profile distinguishes it from both existing AD treatments and other dopamine agonists through several key characteristics: (1) selective amyloid-modulating properties through D2 receptor activation;[88] (2) anti-inflammatory mechanisms via PP2A/JNK pathway modulation;[12] (3) neuroprotective effects against glutamate excitotoxicity;[87] and (4) established safety profile from decades of clinical use.[83-85]

10.3 Integration with Current Treatment Paradigms

The mechanistic differences between bromocriptine and existing AD treatments suggest strong potential for combination approaches. With cholinesterase inhibitors, complementary mechanisms may provide additive cognitive benefits. With anti-amyloid therapies, bromocriptine's amyloid-modulating effects could enhance clearance approaches. With anti-inflammatory agents, synergistic effects on neuroinflammation may provide greater neuroprotection.

10.4 Economic and Healthcare System Implications

Bromocriptine's potential advantages include lower development costs due to repurposing, established manufacturing and supply chains, potential for generic competition to reduce long-term costs, and oral administration, thereby avoiding infusion-related costs. The healthcare system impact could include reduced caregiver burden through improved outcomes, potential delay in nursing home placement, and integration with existing clinical care pathways.

11. Research Gaps and Future Directions

Several critical knowledge gaps limit the current understanding of the potential of dopaminergic therapy in AD. The optimal timing of intervention remains unclear, with uncertainty about whether bromocriptine is most effective in preclinical, early, or moderate AD stages. Dose-response relationships need careful delineation to establish the minimum effective dose for cognitive benefits versus neuroprotection.

Clinical evidence gaps significantly limit the translation of promising preclinical findings to clinical practice. Long-term safety data in AD populations extending beyond two years are essential for establishing the risk-benefit profile. Comparative effectiveness studies versus standard care are needed to demonstrate clinical value and guide treatment selection.

12. CONCLUSIONS

Bromocriptine represents a promising therapeutic candidate for AD treatment through its multi-target approach addressing dopaminergic deficits, amyloid pathology, and neuroinflammation. The evidence supports a paradigm shift from single-pathway therapeutic approaches toward integrated, multi-target interventions that recognize the complex, interconnected nature of AD pathophysiology.

The convergence of mechanistic understanding, clinical need, and therapeutic opportunity positions dopaminergic targeting through bromocriptine as a transformative approach to AD treatment. Unlike current therapies, which offer modest benefits and significant limitations, bromocriptine holds potential for meaningful clinical improvements through the restoration of neurotransmitter balance, suppression of neuroinflammation, and preservation of synaptic function.

However, clinical translation requires carefully designed trials considering dosing optimization, patient stratification, and safety profiles in elderly populations. The establishment of predictive biomarkers and the development of combination therapy protocols will be crucial for maximizing therapeutic potential while ensuring patient safety.
The successful development of dopaminergic therapies for AD could catalyze a fundamental transformation in how the field approaches neurodegenerative disease treatment, potentially revolutionizing the entire field of neurodegeneration therapeutics and providing hope for patients and families affected by these devastating conditions.

REFERENCES

1. Alzheimer's Disease International, "Dementia statistics," 2024. [Online]. Available: https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/
2. Alzheimer's Association, "2024 Alzheimer's disease facts and figures," Alzheimer's & Dementia, 2024; 20(5): 3708-3821.
3. D. D. Li, Y. H. Zhang, W. Zhang, and P. Zhao, "Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease," Front. Neurosci., 2019; 13: p. 472,.
4. C. H. van Dyck et al., "Lecanemab in early Alzheimer's disease," N. Engl. J. Med., 2023; 388(1): 9-21.
5. S. J. Kim et al., "Amyloid-related imaging abnormalities in the era of anti-amyloid beta monoclonal antibodies for Alzheimer's disease: Recent updates on clinical and imaging features and MRI monitoring," Korean J. Radiol., 2024; 25(6): 566-579.
6. Eisai Co., Ltd., "Eisai to present updated dual-acting lecanemab data, research on blood biomarkers for predicting presence of amyloid in the brain and new findings on the anti-MTBR tau antibody E2814 at the 17th Clinical Trials for Alzheimer's," News release, 2024.
7. N. Kemppainen et al., "Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease," Eur. J. Neurosci., 2003; 18(1): 149-154.
8. A. Nobili et al., "Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer's disease," Nat. Commun., 2017; 8: p. 14727.
9. Y. Zhang, Y. Liang, and Y. Gu, "The dopaminergic system and Alzheimer's disease," Neural Regen. Res., 2025; 20(9): 2495-2512.

10. A. Martorana, Z. Esposito, and G. Koch, "Beyond the cholinergic hypothesis: Do current drugs work in Alzheimer's disease?" CNS Neurosci. Ther., 2019; 16(4): 235-245,.
11. RIKEN, "Dopamine treatment alleviates symptoms in Alzheimer's disease," Press release, Aug. 7, 2024.
12. X. Liu et al., "Dopamine D2 receptor agonist bromocriptine ameliorates Aβ1-42-induced memory deficits and neuroinflammation in mice," Eur. J. Pharmacol., 2023; 938: p. 175443.
13. R. Mahajan, "Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes," Indian J. Pharmacol., 2009; 41(4): 197-198.
14. DrugBank, "Bromocriptine: Uses, interactions, mechanism of action," DrugBank Online, 2024.
15. B. A. Gazdag et al., "Altered neurochemistry in Alzheimer's disease: Targeting neurotransmitter receptor mechanisms and therapeutic strategy," Neurophysiology, 2019; 51(6): 423-440.
16. S. L. James et al., "Global, regional, and national incidence, prevalence, and years lived with disability for 354 Diseases and Injuries for 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017," The Lancet, 2018; 392(10159): 1789-1858.
17. "2024 Alzheimer's disease facts and figures," Alzheimer's and Dementia, 2024; 20(5): 3708-3821.
18. C. Franceschi et al., "The Continuum of Aging and Age-Related Diseases: Common Mechanisms but Different Rates," Front. Med. (Lausanne), 2018; 5: p. 1.
19. A. Wimo et al., "The worldwide costs of dementia in 2019," Alzheimer's Dement, 2023; 19(7): 2865.
20. "Health Days 2020 - World Alzheimer's Day," Ministry of Health Saudi Arabia, 2020.
21. B. A. Kent and R. E. Mistlberger, "Sleep and hippocampal neurogenesis: Implications for Alzheimer's disease," Front. Neuroendocrinol, 2017; 45: 35-52.
22. O. Mahdi et al., "Chemicals used for the induction of Alzheimer's disease-like cognitive dysfunctions in rodents," Biomed. Res. Ther., 2019; 6(11): 3460-3484.
23. J. Hardy and D. J. Selkoe, "The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics," Science, 2002; 297(5580): 353-356.
24. R. H. Swerdlow and S. M. Khan, "A 'mitochondrial cascade hypothesis' for sporadic Alzheimer's disease," Med. Hypotheses, 2004; 63(1): 8-20.
25. R. H. Swerdlow, "Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies," J. Neurosci. Res., 2007; 3416-3428.
26. R. H. Swerdlow and S. J. Kish, "Mitochondria in Alzheimer's disease," 2002.
27. A. R. Duan et al., "Interactions between Tau and Different Conformations of Tubulin: Implications for Tau Function and Mechanism," J. Mol. Biol., 2017; 429(9): 1424-1438.
28. N. Crespo-Biel, C. Theunis, and F. Van Leuven, "Protein Tau: Prime Cause of Synaptic and Neuronal Degeneration in Alzheimer's Disease," Int. J. Alzheimer's Dis., 2012; 2012.
29. H. A. M. M. Almansoub et al., "Tau Abnormalities and the Potential Therapy in Alzheimer's Disease," J. Alzheimer's Dis., 2019; 67(1): 13-33.
30. M. J. Guerrero-Muñoz, J. Gerson, and D. L. Castillo-Carranza, "Tau Oligomers: The Toxic Player at Synapses in Alzheimer's Disease," Front. Cell Neurosci., 2015; 9: 1-10.
31. F. Clavaguera et al., "Transmission and spreading of tauopathy in transgenic mouse brain," Nat. Cell Biol., 2009; 11(7): 909-913.

32. B. B. Holmes and M. I. Diamond, "Prion-like properties of Tau protein: The importance of extracellular Tau as a therapeutic target," J. Biol. Chem., 2014; 289(29): 19855-19861.
33. M. Fá et al., "Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory," Sci. Rep., 2016; 6.
34. S. Muralidar et al., "Role of tau protein in Alzheimer's disease: The prime pathological player," Int. J. Biol. Macromol., 2020; 163: 1599-1617.
35. R. Kayed et al., "Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis," Science, 2003; 300(5618): 486-489.
36. S. C. Fuller, "A study of the neurofibrils in dementia paralytica, dementia senilis, chronic alcoholism, cerebral lues and microcephalic idiocy," Am. J. Psychiatry, 2006; 63(4): 415-468.
37. H. Zetterberg, K. Blennow, and E. Hanse, "Amyloid β and APP as biomarkers for Alzheimer's disease," Exp. Gerontol., 2010; 45(1): 23-29.
38. J. Ballesteros-Álvarez et al., "Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer's disease," Geroscience, 2023; 45(2): 1095-1113.
39. M. P. Murphy and H. Levine, "Alzheimer's disease and the amyloid-beta peptide," J. Alzheimer's Dis., 2010; 19(1): 311-323.
40. D. M. Bowen et al., "Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies," Brain, 1976; 99(3): 459-496.
41. P. Davies and A. J. F. Maloney, "Selective loss of central cholinergic neurons in Alzheimer's disease," Lancet, 1976; 2(8000): 1403.
42. P. J. Whitehouse et al., "Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis," Ann. Neurol., 1981; 10(2): 122-126.
43. M. M. Mesulam, "A horseradish peroxidase method for the identification of the efferents of acetyl cholinesterase-containing neurons," J. Histochem. Cytochem, 1976; 24(12): 1281-1285.
44. D. A. Drachman and J. Leavitt, "Human memory and the cholinergic system. A relationship to aging?" Arch. Neurol., 1974; 30(2): 113-121.
45. W. K. Summers et al., "Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type," N. Engl. J. Med., 1986; 315(20): 1241-1245.
46. S. D. Brinkman and S. Gershon, "Measurement of cholinergic drug effects on memory in Alzheimer's disease," Neurobiol. Aging, 1983; 4(2): 139-145.
47. A. V. Terry and J. J. Buccafusco, "The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development," J. Pharmacol. Exp. Ther., 2003; 306(3): 821-827.
48. M. E. Hasselmo, B. P. Anderson, and J. M. Bower, "Cholinergic modulation of cortical associative memory function," J. Neurophysiol., 1992; 67(5): 1230-1246.
49. E. Mohandas, V. Rajmohan, and B. Raghunath, "Neurobiology of Alzheimer's disease," Indian J. Psychiatry, 2009; 51(1): 55-61.
50. L. Tan, "Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis," J. Alzheimer's Dis., 2014; 41(2): 615-631.

51. "Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients," PubMed, accessed May 2, 2023.
52. E. Shearman et al., "Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study," Brain Res. Bull., 2006; 69(2): 204-213.
53. D. D. Li et al., "Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease," Front. Neurosci, 2019; 13.
54. E. Shearman et al., "Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study," Brain Res. Bull., 2006; 69(2): 204-213.
55. L. Zhang, F. M. Zhou, and J. A. Dani, "Cholinergic drugs for alzheimer's disease enhance in vitro dopamine release," Mol. Pharmacol., 2004; 66(3): 538-544.
56. R. S. Naik et al., "Effects of rivastigmine and donepezil on brain acetylcholine levels in acetylcholinesterase-deficient mice," J. Pharm. Pharm. Sci., 2009; 12(1): 79-85.
57. R. J. Polinsky, "Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease," Clin. Ther., 1998; 20(4): 634-647.
58. K. Higashino et al., "Rivastigmine improves isolation rearing-induced prepulse inhibition deficits via muscarinic acetylcholine receptors in mice," Psychopharmacology (Berl.), 2016; 233(3): 521-528.
59. D. A. Butterfield et al., "Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists," J. Alzheimer's Dis., 2002; 4(3): 193-201.
60. G. Gibson, D. Allsop, and B. Austen, "Induction of cellular oxidative stress by the beta-amyloid peptide involved in Alzheimer's disease," Protein Pept. Lett., 2004; 11(3): 257-270.
61. H. Mohmmad Abdul et al., "Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells," J. Neurochem., 2006; 96(5): 1322-1335.
62. R. Sultana and D. A. Butterfield, "Redox proteomics studies of in vivo amyloid beta-peptide animal models of Alzheimer's disease," Proteomics Clin. Appl., 2008; 2(5): 685-696.
63. C. Cheignon et al., "Oxidative stress and the amyloid beta peptide in Alzheimer's disease," Redox Biol., 2018; 14: 450-464.
64. J. Teixeira, T. Silva, P. Andrade, and F. Borges, "Alzheimer's disease and antioxidant therapy: how long how far?" Curr. Med. Chem., 2013; 20(24): 2939-2952.
65. V. Balendra and S. K. Singh, "Therapeutic potential of astaxanthin and superoxide dismutase in Alzheimer's disease," Open Biol., 2021; 11(6).
66. Á. Casado et al., "Lipid peroxidation and antioxidant enzyme activities in vascular and alzheimer dementias," Neurochem. Res., 2008; 33(3): 450-458.
67. L. Esposito et al., "Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology," J. Neurosci., 2006; 26(19): 5167-5179.
68. M. C. Puertas et al., "Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia," Exp. Gerontol., 2012; 47(8): 625-630.
69. M. Bolós, J. R. Perea, and J. Avila, "Alzheimer's disease as an inflammatory disease," Biomol. Concepts, 2017; 8(1): 37-43.
70. R. Guerreiro et al., "TREM2 variants in Alzheimer's disease," N. Engl. J. Med., 2013; 368(2): 117-127.

71. Y. S. Kim, K. J. Lee, and H. Kim, "Serum tumour necrosis factor-α and interleukin-6 levels in Alzheimer's disease and mild cognitive impairment," Psychogeriatrics, 2017; 17(4): 224-230.
72. A. A. Helmy et al., "Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias," Neurodegener. Dis., 2012; 9(2): 81-86.
73. D. Shamim and M. Laskowski, "Inhibition of Inflammation Mediated Through the Tumor Necrosis Factor α Biochemical Pathway," J. Cent. Nerv. Syst. Dis., 2017; 9.
74. W. S. T. Sue, "Perispinal etanercept: Potential as an Alzheimer therapeutic," J. Neuroinflammation, 2008; vol. 5.
75. R. Nardone et al., "Dopamine differently modulates central cholinergic circuits in patients with Alzheimer disease and CADASIL," J. Neural Transm., 2014; 121(10): 1313-1320.
76. H. Hagena and D. Manahan-Vaughan, "Dopamine D1/D5, But not D2/D3, receptor dependency of synaptic plasticity," Front. Synaptic Neurosci, 2016; 8: p. 31.
77. E. Nam et al., "Regulatory Activities of Dopamine and Its Derivatives toward Metal-Free and Metal-Induced Amyloid-β Aggregation," ACS Chem. Neurosci., 2018; 9(11): 2655-2666.
78. P. Donthamsetti et al., "Arrestin recruitment to dopamine D2 receptor mediates locomotion but not incentive motivation," Mol. Psychiatry, 2020; 25(9): 2086-2100.
79. Y. Zhang, Y. Liang, and Y. Gu, "The dopaminergic system and Alzheimer's disease," Neural Regen. Res., 2025; 20(9): 2495-2512.
80. T. M. Karrer et al., "Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults," Neurobiol. Aging, 2017; 57: 36-46.
81. G. Koch et al., "Dopaminergic Modulation of Cortical Plasticity in Alzheimer's Disease Patients," Neuropsychopharmacology, 2014; 39(11): 2654-2661.
82. N. Kemppainen et al., "Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease," Eur. J. Neurosci., 2003; 18(1): 149-154.
83. R. Mahajan, "Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes," Indian J. Pharmacol., 2009; 41(4): 197.
84. P. Singh et al., "Hyperprolactinemia: An often missed cause of male infertility," J. Hum. Reprod. Sci., 2011; 4(2): 102.
85. R. I. G. Holt, A. H. Barnett, and C. J. Bailey, "Bromocriptine: old drug, new formulation and new indication," Diabetes Obes. Metab., 2010; 12(12): 1048-1057.
86. S. Perachon, J. C. Schwartz, and P. Sokoloff, "Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors," Eur. J. Pharmacol., 1999; 366(2-3): 293-300.
87. X. Liu et al., "Dopamine D2 receptor agonist Bromocriptine ameliorates Aβ1-42-induced memory deficits and neuroinflammation in mice," Eur. J. Pharmacol., 2023; 938: p. 175443.
88. T. Kondo et al., "iPSC-Based Compound Screening and In Vitro Trials Identify a Synergistic Anti-amyloid β Combination for Alzheimer's Disease," Cell Rep., 2017; 21(8): 2304-2312.